Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Iobenguane I-131 - Progenics Pharmaceuticals

Drug Profile

Iobenguane I-131 - Progenics Pharmaceuticals

Alternative Names: 131-I-metaiodobenzylguanidine; 131-I-MIGB; 131I-iobenguane - Progenics Pharmaceuticals; 131I-MIBG - Progenics Pharmaceuticals; 3-iodobenzylguanidine-I-123; Azedra; HSA I-131 MIBG; I-131 mIBG; I-131-iobenguane; Iobenguane-I123-injection; Iobenguane-I131; Iobenguane-sulfate; Iodine-123 metaiodobenzylguanidine - Progenics Pharmaceuticals; Iodine-131 iobenguane - Progenics Pharmaceuticals; Iodine-131 metaiodobenzylguanidine - Progenics Pharmaceuticals; Iodine-131-metaiodobenzylguanidine; Iodine-I-131-metaiodobenzylguanidine; m-Iodobenzylguanidine-sulfate; Meta-iodobenzylguanidine; Metaiodobenzylguanidine-I-123; Metaiodobenzylguanidine-I-131; Metaiodobenzylguanidine-sulfate; MIBG; MIP-120T; Ultratrace I-131-MIBG; Ultratrace iobenguane I 131; Ultratrace MIBG; Ultratrace-iobenguane-I-131

Latest Information Update: 14 Jun 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Molecular Insight Pharmaceuticals
  • Developer Progenics Pharmaceuticals
  • Class Antineoplastics; Guanidines; Imaging agents; Iodobenzenes; Radiopharmaceutical diagnostics; Small molecules; Sulfates
  • Mechanism of Action Cell death stimulants; Neuron inhibitors; Poly(ADP-ribose) polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuroendocrine tumours
  • New Molecular Entity No

Highest Development Phases

  • Marketed Neuroendocrine tumours
  • Discontinued Neuroblastoma

Most Recent Events

  • 14 Jun 2023 Discontinued - Phase-II for Neuroblastoma (In children) in USA (IV) (Lantheus pipeline June 2023)
  • 03 Mar 2021 Efficacy data related to biomarkers impact from a phase IIb trial in Neuroendocrine tumours presented at the 103rd Annual Meeting of the Endocrine Society (ENDO-2021)
  • 16 Jun 2020 Progenics Pharmaceuticals has been acquired by Lantheus Holdings
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top